The Strategic Pivot Toward External Innovation from Biopharma Patent Cliff 2026
The biopharma patent cliff 2026 represents a “super-cliff” where an estimated $350 billion in global revenue is at risk by 2030. Industry leaders are no longer relying solely on organic…